<DOC>
	<DOCNO>NCT01750580</DOCNO>
	<brief_summary>To assess safety tolerability , characterize dose-limiting toxicity ( DLTs ) , identify maximally tolerate dose ( MTD ) BMS-986015 give combination ipilimumab subject select advanced ( metastatic and/or unresectable ) solid tumor .</brief_summary>
	<brief_title>Safety Study BMS-986015 ( Anti-KIR ) Combination With Ipilimumab Subjects With Selected Advanced Tumor</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Histologic confirmation one follow solid tumor advance ( unresectable metastatic ) dose escalation cohort expansion : NonSmall Cell Lung Cancer ( NSCLC ) , Castrate Resistant Prostate Cancer ( CRPC ) , Melanoma ( MEL ) At least one measurable lesion baseline Computed tomography ( CT ) Magnetic resonance imaging ( MRI ) per Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 criteria Biopsies : Subjects melanoma cohort must least 1 tumor site biopsied acceptable clinical risk Eastern Cooperative Oncology Group ( ECOG ) status 0 1 Estimated life expectancy ≥ 12 week White blood cell ( WBC ) ≥2000/μL , Neutrophils ≥1500/μL , Platelets ≥ 100x1000/μL , Hemoglobin ≥ 8.5 g/dL , creatinine ≤ 1.5 X upper limit normal ( ULN ) mL/min , Alanine aminotransferase ( ALT ) Aspartate aminotransferase ( AST ) ≤ 3x ULN Normal thyroid function stable hormone supplementation Participation prior clinical study BMS936558 ipilimumab overall survival list primary/coprimary endpoint Subjects know suspected brain metastasis Subjects active autoimmune disease , uncontrolled significant cardiovascular disease Prior therapy anti Cytotoxic TLymphocyte Antigen 4 ( CTLA4 ) antibody anti Killer cell immunoglobulinlike receptor ( KIR ) antibody Grade 2 neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>